Ablation of sarcolipin results in atrial remodeling

American Journal of Physiology - Cell Physiology

Volumn 302, Issue 12, 2012, Pages

  Xie, Lai Hua ^a   Shanmugam, Mayilvahanan ^a   Park, Ji Yeon ^a   Zhao, Zhenghang ^a   Wen, Hairuo ^a   Tian, Bin ^a   Periasamy, Muthu ^b   Babu, Gopal J ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Action potential duration; Arrhythmias; Calcium; Fibrosis; Sarcoplasmic reticulum Ca 2+ adenosinetriphosphatase

Indexed keywords

CALCIUM; CALCIUM CHANNEL L TYPE; COLLAGEN; PROTEIN; SARCOLIPIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SCLEROPROTEIN; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ARTICLE; ATRIAL REMODELING; CALCIUM SIGNALING; CONTROLLED STUDY; FIBROSING ALVEOLITIS; GENE EXPRESSION; HEART ATRIUM MUSCLE; HEART DEPOLARIZATION; HEART REPOLARIZATION; HEART VENTRICLE REMODELING; MEASUREMENT; MOUSE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL;

ACTION POTENTIALS; AGING; ANIMALS; ARRHYTHMIAS, CARDIAC; ATRIAL FUNCTION; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; COLLAGEN; FIBROSIS; GENE EXPRESSION REGULATION; GENOTYPE; HEART ATRIA; HOMEOSTASIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE PROTEINS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PHENOTYPE; PROTEOLIPIDS; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TIME FACTORS;

EID: 84862603334     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00425.2011     Document Type: Article

References (55)

1. 2+ ATPase (SERCA2a) activity and impairs cardiac function in mice. Proc Natl Acad Sci USA 101: 9199-9204, 2004.
2. Babu GJ, Bhupathy P, Carnes CA, Billman GE, Periasamy M. Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology. J Mol Cell Cardiol 43: 215-222, 2007.
3. Babu GJ, Bhupathy P, Petrashevskaya NN, Wang H, Raman S, Wheeler D, Jagatheesan G, Wieczorek D, Schwartz A, Janssen PM, Ziolo MT, Periasamy M. Targeted overexpression of sarcolipin in the mouse heart decreases sarcoplasmic reticulum calcium transport and cardiac contractility. J Biol Chem 281: 3972-3979, 2006.
4. Babu GJ, Bhupathy P, Timofeyev V, Petrashevskaya NN, Reiser PJ, Chiamvimonvat N, Periasamy M. Ablation of sarcolipin enhances sarcoplasmic reticulum calcium transport and atrial contractility. Proc Natl Acad Sci USA 104: 17867-17872, 2007.
5. Babu GJ, Zheng Z, Natarajan P, Wheeler D, Janssen PM, Periasamy M. Overexpression of sarcolipin decreases myocyte contractility and calcium transient. Cardiovasc Res 65: 177-186, 2005.
6. + transport in cardiac myocytes. Implications for excitation-contraction coupling. IUBMB Life 61: 215-221, 2009.
7. Blaich A, Welling A, Fischer S, Wegener JW, Kostner K, Hofmann F, Moosmang S. Facilitation of murine cardiac L-type Ca(v)1.2 channel is modulated by calmodulin kinase II-dependent phosphorylation of S1512 and S1570. Proc Natl Acad Sci USA 107: 10285-10289, 2010.
8. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 44: 121-131, 1999.
9. 2+ leak promotes atrial fibrillation in mice. J Clin Invest 119: 1940-1951, 2009.
10. 2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 110: 2651-2657, 2004.
11. Dobrev D. Atrial Ca(2+) signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn Schmiedebergs Arch Pharmacol 381: 195-206, 2010.
12. Dobrev D. Electrical remodeling in atrial fibrillation. Herz 31: 108-112; quiz 142-103, 2006.
13. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, Knaut M, Ravens U. The G protein-gated potassium current I(K,ACh) is con-stitutively active in patients with chronic atrial fibrillation. Circulation 112: 3697-3706, 2005.
14. Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 52: 293-299, 2008.
15. 2+ signaling. J Mol Cell Cardiol 46: 448-451, 2009.
16. Ehrlich JR, Cha TJ, Zhang L, Chartier D, Villeneuve L, Hebert TE, Nattel S. Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol 557: 583-597, 2004.
17. Everett TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4: S24-S27, 2007.
18. Friedrichs GS. Experimental models of atrial fibrillation/flutter. J Pharmacol Toxicol Methods 43: 117-123, 2000.
19. Gramley F, Lorenzen J, Koellensperger E, Kettering K, Weiss C, Munzel T. Atrial fibrosis and atrial fibrillation. The role of the TGF-beta(1) signaling pathway. Int J Cardiol 143: 405-413, 2010.
20. Gramolini AO, Trivieri MG, Oudit GY, Kislinger T, Li W, Patel MM, Emili A, Kranias EG, Backx PH, Maclennan DH. Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation. Proc Natl Acad Sci USA 103: 2446-2451, 2006.
21. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 391: 85-100, 1981.
22. 2+ exchange: cardiac-specific knockout of NCX1. Circ Res 95: 604-611, 2004.
23. Hove-Madsen L, Llach A, Bayes-Genis A, Roura S, Rodriguez Font E, Aris A, Cinca J. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation 110: 1358-1363, 2004.
24. Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol 59: 1-30, 2010.
25. Lemke T, Welling A, Christel CJ, Blaich A, Bernhard D, Lenhardt P, Hofmann F, Moosmang S. Unchanged beta-adrenergic stimulation of cardiac L-type calcium channels in Cav 1.2 phosphorylation site S1928A mutant mice. J Biol Chem 283: 34738-34744, 2008.
26. Li N, Wang T, Wang W, Cutler MJ, Wang Q, Voigt N, Rosenbaum DS, Dobrev D, Wehrens XH. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. Circ Res 110: 465-470, 2010.
27. Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65: 1489-1508, 2008.
28. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosem-blit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376, 2000.
29. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 1: 62-73, 2008.
30. Olgin JE, Verheule S. Transgenic and knockout mouse models of atrial arrhythmias. Cardiovasc Res 54: 280-286, 2002.
31. 2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res 77: 265-273, 2008.
32. Periasamy M, Huke S. SERCA pump level is a critical determinant of Ca(2+homeostasis and cardiac contractility. J Mol Cell Cardiol 33: 1053-1063, 2001.
33. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 12: 189-208, 2008.
34. 2+ fluxes. Ann N Y Acad Sci 1099: 310-314, 2007.
35. 2+/ calmodulin-dependent protein kinase II. Am J Physiol Heart Circ Physiol 295: H1669-H1683, 2008.
36. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91: 265-325, 2011.
37. Severs NJ, Bruce AF, Dupont E, Rothery S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res 80: 9-19, 2008.
38. Shanmugam M, Gao S, Hong C, Fefelova N, Nowycky MC, Xie LH, Periasamy M, Babu GJ. Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractility. Cardiovasc Res 89: 353-361, 2011.
39. Shanmugam M, Molina CE, Gao S, Severac-Bastide R, Fischmeister R, Babu GJ. Decreased sarcolipin protein expression and enhanced sarco(endo)plasmic reticulum Ca(2+) uptake in human atrial fibrillation. Biochem Biophys Res Commun 410: 97-101, 2011.
40. Sood S, Chelu MG, van Oort RJ, Skapura D, Santonastasi M, Dobrev D, Wehrens XH. Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heart Rhythm 5: 1047-1054, 2008.
41. 2+ release on action potentials and afterdepolarizations in guinea pig ventricular myocytes. Am J Physiol Heart Circ Physiol 285: H2552-H2562, 2003.
42. Sun H, Gaspo R, Leblanc N, Nattel S. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation 98: 719-727, 1998.
43. Tessier S, Karczewski P, Krause EG, Pansard Y, Acar C, Lang-Lazdunski M, Mercadier JJ, Hatem SN. Regulation of the transient outward K(+) current by Ca(2+)/calmodulin-dependent protein kinases II in human atrial myocytes. Circ Res 85: 810-819, 1999.
44. Uemura N, Ohkusa T, Hamano K, Nakagome M, Hori H, Shimizu M, Matsuzaki M, Mochizuki S, Minamisawa S, Ishikawa Y. Down-regulation of sarcolipin mRNA expression in chronic atrial fibrillation. Eur J Clin Invest 34: 723-730, 2004.
45. Van Wagoner DR. Recent insights into the pathophysiology of atrial fibrillation. Semin Thorac Cardiovasc Surg 19: 9-15, 2007.
46. Van Wagoner DR, Nerbonne JM. Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 32: 1101-1117, 2000.
47. 2+ currents and human atrial fibrillation. Circ Res 85: 428-436, 1999.
48. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 80: 772-781, 1997.
49. Vangheluwe P, Schuermans M, Zador E, Waelkens E, Raeymaekers L, Wuytack F. Sarcolipin and phospholamban mRNA and protein expression in cardiac and skeletal muscle of different species. Biochem J 389: 151-159, 2005.
50. Vest JA, Wehrens XH, Reiken SR, Lehnart SE, Dobrev D, Chandra P, Danilo P, Ravens U, Rosen MR, Marks AR. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111: 2025-2032, 2005.
51. Volders PG, Vos MA, Szabo B, Sipido KR, de Groot SH, Gorgels AP, Wellens HJ, Lazzara R. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 46: 376-392, 2000.
52. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92: 1954-1968, 1995.
53. Wit AL, Boyden PA. Triggered activity and atrial fibrillation. Heart Rhythm 4: S17-S23, 2007.
54. Yeh YH, Wakili R, Qi XY, Chartier D, Boknik P, Kaab S, Ravens U, Coutu P, Dobrev D, Nattel S. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 1: 93-102, 2008.
55. Yue DT, Herzig S, Marban E. Beta-adrenergic stimulation of calcium channels occurs by potentiation of high-activity gating modes. Proc Natl Acad Sci USA 87: 753-757, 1990.